MEDIBANK PRIVATE LTD Overview
Medibank is Australia's largest listed private health insurer and is building a broader health-services business. It holds about 26.3% of the resident private health insurance (PHI) market through the Medibank and ahm brands (APRA, March 2026). It also insures about 346,000 non-resident policy units (students, workers, visitors). It is the preferred provider of overseas student health cover at nearly half of Australian universities (FY2024 release).
The group positions itself as a "health company". Its Medibank Health segment (wellbeing, primary care, and community and acute care) is run through Amplar Health. This segment earned A$100.7m in FY2026, up 31.3%. It now includes 168 owned or majority-owned GP clinics following the A$163.5m Better Medical acquisition. FY2026 underlying NPAT was A$636.8m on group revenue of A$9.1bn, with a fully franked dividend of 19.2c.
Management's 2030 aspirations are:
-
Medibank Health profit of more than A$200m.
-
Resident market share above 26.8%.
-
Engagement with about 10 million people.
The 2022 cybercrime event remains the main legal overhang.
What Medibank does. Medibank underwrites and distributes private health insurance:
Resident PHI: hospital and extras cover under the Medibank (premium/mainstream) and ahm (value) brands.
Non-resident PHI: Overseas Student Health Cover, Overseas Visitor and worker covers.
Through Medibank Health it also delivers health services:
Wellbeing: Live Better rewards, corporate health, and "financial wellbeing" distribution of travel, pet, life, income-protection, car and home insurance.
Primary care: Myhealth (92.7% owned), Better Medical (100%), Amplar Health virtual care and online doctor.
Community and acute care: Amplar Health home hospital and transition care, plus joint-venture short-stay hospitals and mental-health facilities.
Company's own framing (FY2026 Investor Presentation, paraphrased).
-
Purpose: "Better Health for Better Lives".
-
Vision: to create the best health and wellbeing for Australia.
-
Five operating segments: resident health insurance, non-resident health insurance, wellbeing, primary care, and community and acute care.
-
Differentiation: supporting whole-of-health needs, deepening customer relationships, driving change in the health system, and giving customers more value, choice and control.
Revenue model.
The segment figures above add to slightly more than the A$9,115.2m group revenue from external customers (they include some intra-group revenue). Group revenue from external customers is the reported total.
Value-chain position. Medibank is the payer at the centre of the private health system. It collects premiums and pays benefits to private hospitals (64% of resident hospital claims), medical specialists (14%), prostheses suppliers (12%) and public hospitals (7%). Extras benefits go to dental (55% of extras), optical (16%), physiotherapy, chiropractic and others (FY2026 presentation). It is increasingly vertically integrating into care delivery (GP clinics, home hospital, short-stay JV hospitals) to manage claims costs and engage customers.
Customers and end-markets.
-
Australian households (singles, couples, families); 2,025,300 resident policyholders and 3.09m hospital lives.
-
Corporate clients (record corporate policyholder growth in FY2026).
-
International students, workers and visitors.
-
Public payers: state health departments buying home hospital and transition care, and Medicare via GP billing.
Independent characterisation. Medibank is a capital-light, cash-generative, defensive franchise in a regulated oligopoly. Its insurance economics rest on a broadly stable resident gross margin of about 16–17% and an industry-low management expense ratio of about 8%. Investment income adds roughly a fifth of pre-tax profit. The strategic bet is that owning primary care and out-of-hospital care will lower claims inflation, raise retention and create an earnings stream outside regulated premiums. That stream is about 12% of group operating profit today. The main constraint is regulatory: premium rises need ministerial approval, and the A$250m APRA capital overlay remains until cyber remediation is complete.
Strategy
Strategic pillars (FY2026 presentation; Medibank's own labels).
-
Deliver leading experiences. Increase advocacy and trust; simplify customer experiences; reinvent ways of working with AI and autonomous teams; lead the health transition.
-
Differentiate our insurance business. Disciplined resident growth in priority segments (families, those new to the industry, corporate, direct channels); return to non-resident growth; integrated PHI and health propositions.
-
Expand in health. Increase wellbeing engagement; accelerate GP-led primary care; expand home-based and transitional care.
-
Continue to strengthen our foundations. Risk culture ("Risk Fit" framework), technology simplification, automation and AI, productivity.
2030 aspirations and milestones.
The strategy also targets incremental PHI value equal to about 5% of PHI operating profit between FY2025 and FY2030 through health engagement.
Initiatives in the last 24 months.
-
Better Medical acquisition (A$163.5m).
-
Online Doctor expanded to all Medibank customers.
-
Recover Boost launched.
-
"Customer first" program.
-
AI scaling across the business.
-
Risk Fit framework.
-
A$50m five-year mental-health commitment (A$11.5m in FY2026).
-
More than A$40m provided to private hospitals for sustainability and innovation (FY2026).
-
Corporate health platform investment (about A$10m additional Medibank Health spend).
-
About A$10m a year of productivity savings: A$132.4m cumulative in under a decade.
-
Medibank Group brand launch (1 Oct 2026).
-
First ASRS-aligned Sustainability Report (Sep 2026).
FY2027 guidance (20 Aug 2026).
-
Grow resident market share in a disciplined way, including improved Medibank-brand momentum.
-
Resident PHI gross margin broadly consistent with FY2026, subject to the April 2027 premium round.
-
Solid non-resident gross profit growth.
-
Medibank Health segment profit growth of about 25%, including a full year of Better Medical.
-
About A$10m of further productivity savings.
-
HI expense growth of about 5.4% (per Rivkin summary).
-
Cyber costs below A$20m.
-
Dividend payout range of 75–85% of underlying NPAT.
Products & Services
A. Health Insurance — resident
B. Health Insurance — non-resident
C. Medibank Health — Wellbeing
D. Medibank Health — Primary care (Amplar Health network)
E. Medibank Health — Community and acute care
Pricing: PHI premiums are publicly listed by product and state but not summarised in filings. Medibank's average resident premium increase was 3.48% in FY2025 and 4.27% in FY2026 (FY2026 presentation). The 1 April 2026 increase averaged 5.1% (CHOICE).
Product Portfolio
| Product / brand | Description | Target customer | Notes |
|---|---|---|---|
Medibank (brand) | Full-service insurer with hospital tiers (Basic, Bronze, Silver, Gold under federal product reforms) and extras | Mainstream and premium households, families, corporates | 1,448,100 policyholders at FY2026 (+0.6%); acquisition rate 9.9%, lapse 9.3% |
ahm (brand) | Value-oriented, digital-first insurer | Price-sensitive and younger customers | 577,200 policyholders (+2.4%); direct joins rose to 51% of ahm joins in FY2026 |
Members' Choice / Members' Choice Advantage networks | Extras provider networks (dental, optical, physio, chiro, podiatry, acupuncture, remedial massage) offering lower out-of-pocket costs | All Medibank extras customers | About A$243m in customer savings in FY2026 (+6%); about 4,000 provider locations |
No-gap hospital program | Medibank-funded procedures with no out-of-pocket costs, including joint replacements | Hospital customers | 1 in 5 Medibank-funded joint replacements in Melbourne and Sydney delivered in a no-gap hospital |
Recover Boost | Recovery-support benefit launched in FY2026 | Medibank and ahm customers | Launched FY2026 |
Live Better (integrated with cover) | Rewards for healthy behaviour, redeemable for partner products or premium savings | Medibank customers | 1,039k members; A$48.6m in rewards claimed FY2026 (+48%) |
Corporate health insurance | Group schemes for employers | Corporates | Record corporate policyholder growth in FY2026 |
| Product | Description | Target | Notes |
|---|---|---|---|
Overseas Student Health Cover (OSHC) | Visa-compliant cover | International students | Preferred provider at nearly half of Australian universities (FY2024) |
Overseas Workers / Visitors cover | Visa-compliant cover | Skilled and graduate workers, visitors | Worker policy units grew 23% vs 11% growth in skilled and graduate visa grants (FY2026); new visitor products launched |
Lifecycle conversion | Moving students to worker cover and then to resident PHI | Non-residents becoming residents | Resident joins from non-resident rose to 8.4% (FY2026) from 7.5% |
| Offering | Description | Metric (FY2026) |
|---|---|---|
Live Better | Digital rewards and challenges program | 1,039k participants; FY2028 milestone above 1.2m |
Everyday prevention programs | Self-paced digital prevention and recovery programs | 334k enrolments; FY2028 milestone above 380k |
Corporate Health | Workforce mental health and wellbeing services | 15% of accounts engaged; FY2028 milestone above 20% |
Financial wellbeing | Distribution of travel, pet, life, income-protection, car and home insurance (commission-based) | 356k policies (+4.7%); FY2028 milestone above 440k |
Mental health commitment | Five-year A$50m program | A$11.5m invested in FY2026 |
| Offering | Description | Metric |
|---|---|---|
Myhealth Medical Group (92.7%) | GP-led multidisciplinary clinics across eastern Australia | About 105 clinics (Nov 2025 release) |
Better Medical (100%) | 61 GP and medical clinics in VIC, QLD, SA and TAS; about 800 clinicians | Acquired for A$163.5m; contributed A$6.2m in its first six months |
Amplar Health Online Doctor / virtual care | Telehealth GP, 24/7 nursing, health concierge, mental-health triage | Online doctor expanded to all Medibank customers; virtual consults 21.7% of GP consults |
Proactive Primary Care Program | GP-identified at-risk patients with care plans and follow-up | Clinician-guided prevention services 36k; FY2028 milestone 45k |
GP consultations | Total across the network | 4.134m (+26.7%); FY2028 milestone 7m |
| Offering | Description | Metric |
|---|---|---|
Amplar Health Home Hospital (100% owned) | Hospital-in-the-home care for private and public patients | 27.4k acute home health admissions (+13.7%); about 194k bed days saved |
Transition Care Service | Joint service with SA Health / Central Adelaide Local Health Network | Capacity expanded in FY2026 |
Community care | Nursing, allied health and personal care at home | 106.2k visits; FY2028 milestone 155k |
JV short-stay hospitals | East Sydney Day Hospital (49%), Adeney Private Hospital, Melbourne (49%), Western Adelaide Hospital (49%), SydOrtho / MQ Health Orthopaedic Institute (50%) | JV losses A$6.6m; break-even targeted in FY2028 |
Integrated Mental Health (50%) | Mental-health hospitals plus out-of-hospital support | A$27.4m invested to June 2026 |
Financial Narrative
Basis: FY2022 is pre-AASB 17 as originally reported. FY2023 is restated under AASB 17 (original FY2023 values are given in notes). FY2024–FY2026 are as reported. Sources: FY2022 Media Release; FY2023 Appendix 4E and Media Release; FY2024 Media Release; FY2026 Investor Presentation (FY2025–FY2026).
Income statement
Notes: FY2022 PBT not captured (shown as 0): - FY2022 EPS figures are computed from NPAT and about 2,754m shares; the others are reported.
-
FY2023 as originally reported: revenue A$7,355.3m, statutory NPAT A$511.1m, underlying NPAT A$499.6m.
-
The FY2023 restated statutory NPAT (A$308.6m) is depressed by a A$290.1m pre-tax COVID-19 reserve movement. COVID-reserve movements were A$110.8m in FY2024, A$182.8m in FY2025 and nil in FY2026.
-
FY2022 DPS = 6.1c interim + 7.3c final (InvestSMART dividend history), consistent with the stated 9.0% FY2023 increase.
Margins.
Computed from the table above. FY2023 HI gross margin is implied (16.5% less 40bps) and FY2022 is n.d. "Gross profit" and "EBITDA" are not insurance-standard measures. The insurance gross profit equivalent is HI gross profit: A$1,307.2m in FY2024, A$1,396.4m in FY2025 and A$1,460.0m in FY2026. Group EBITDA is n.d.
Growth.
-
Revenue CAGR FY2023–FY2026 on the AASB 17 basis: 5.3% a year (computed).
-
Underlying NPAT CAGR FY2022–FY2026: 10.0% a year (computed; spans the basis change).
-
Operating profit CAGR FY2022–FY2026: 8.2% a year.
Balance sheet and capital
Zeros mark values not captured in the sources reviewed: Total assets: n.d. at group level. APRA reported A$3.91bn total assets and A$1.69bn net assets for the Medibank health benefits fund entity in 2024–25.
Goodwill and intangibles: "intangible and other adjustments" deducted from eligible capital were A$465.9m (FY2025) and A$647.6m (FY2026), including Better Medical goodwill and software.
Debt: no bank borrowings or bonds disclosed. Lease liabilities exist (AASB 16 interest A$17.6m in FY2026 vs A$12.0m in FY2025). Management says it "can raise Tier 2 debt" if needed.
Net debt: net cash; precise figure n.d.
Working capital: not meaningful for an insurer.
Cash flow and capital returns
Not captured: operating cash flow, capex (D&A in HI was A$49.5m in FY2026), free cash flow and dividends paid in cash.
M&A program: A$218m invested in M&A over FY2024–FY2026 against a A$150–250m target (Better Medical release).
Buybacks: none in FY2022–FY2026. The board says it will consider capital management if suitable M&A does not eventuate.
Ratios
FY2025 ROE is n.d. because FY2024 equity was not captured. Current ratio, debt/equity, net debt/EBITDA, interest coverage and cash conversion cycle are not meaningful: Medibank is a debt-free insurer. ROA and ROIC are n.d. without group total assets.
Commentary
Growth: Group revenue has grown 4.7–5.9% a year since FY2024. Drivers are premium indexation (3.5–4.3% average resident increases), modest policy-unit growth (1–2%) and the expanding health-services business (+30.8% in FY2026, partly from Better Medical and full ownership of Amplar Health Home Hospital).
Insurance margins: The resident gross margin was 16.3% in FY2026, still below the pre-COVID FY2019 level of 17.1%. FY2026 included a A$74.8m non-recurring COVID utilisation benefit (about 150bps on hospital claims), which will not recur in FY2027. Management nonetheless guides to a broadly stable resident gross margin.
Investment income: Investment income turned from a A$24.8m loss in FY2022 to A$207.8m in FY2025 as cash rates rose. It fell to A$178.9m in FY2026 as the RBA eased and cash holdings shrank. Each 25bps on the cash rate is worth about A$6.4m.
Statutory vs underlying: The large gap in FY2023–FY2025 reflects COVID-19 reserve accounting, now finalised. FY2026 statutory and underlying NPAT have converged (A$638.7m vs A$636.8m).
Cyber costs: Cyber costs remain non-recurring at A$35–46m a year. FY2027 is guided below A$20m, excluding any penalties or settlements.
Capital: The required capital ratio (13.3%) sits above the 10–12% target only because of the A$250m APRA overlay. If the overlay is removed, about A$250m of capital would be released.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Health Insurance operating profit (AUD Mn) | 592.6 | 651.3 | 692.3 | 741.5 | 769.8 |
Medibank Health segment profit (AUD Mn) | 0 | 44.2 | 60.4 | 76.7 | 100.7 |
Corporate overheads (AUD Mn) | 0 | -47.1 | -52.9 | -55.8 | -57.0 |
Group operating profit (AUD Mn) | 594.1 | 648.4 | 699.8 | 762.4 | 813.5 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Premium revenue (AUD Mn) | 7,903.0 | 8,211.0 | 8,585.1 |
Resident premium revenue (AUD Mn) | 0 | 7,908.8 | 8,267.9 |
Non-resident premium revenue (AUD Mn) | 0 | 302.2 | 317.2 |
Gross profit (AUD Mn) | 1,307.2 | 1,396.4 | 1,460.0 |
Gross margin (%) | 16.5 | 17.0 | 17.0 |
Resident gross margin (%) | 15.9 | 16.2 | 16.3 |
Non-resident gross margin (%) | 34.2 | 36.9 | 34.8 |
Management expenses (AUD Mn) | 614.9 | 654.9 | 690.2 |
Expense ratio (%) | 7.8 | 8.0 | 8.0 |
Operating margin (%) | 8.8 | 9.0 | 9.0 |
Revenue by Segment and Segment Margins & Growth (%) (FY2025–FY2026)
| Sub-segment | FY2025 | FY2026 |
|---|---|---|
Wellbeing revenue (AUD Mn) | 144.9 | 175.5 |
Primary care revenue (AUD Mn) | 244.3 | 316.5 |
Community and acute revenue (AUD Mn) | 96.0 | 142.8 |
Total Medibank Health revenue (AUD Mn) | 485.2 | 634.8 |
Wellbeing operating profit (AUD Mn) | 56.3 | 62.8 |
Primary care operating profit (AUD Mn) | 29.1 | 38.8 |
Community and acute operating profit (AUD Mn) | -0.1 | 10.1 |
Share of loss from JV investments (AUD Mn) | -7.5 | -6.6 |
Medibank Health operating margin (%) | 17.4 | 16.9 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
HI premium revenue growth YoY (%) | 4.0 | 3.9 | 4.6 |
Medibank Health revenue growth YoY (%) | 0 | 0 | 30.8 |
Medibank Health share of segment operating profit (%) | 8.0 | 9.4 | 11.6 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Group revenue from external customers (AUD Mn) | 7,128.5 | 7,807.0 | 8,175.8 | 8,604.0 | 9,115.2 |
Group operating profit (AUD Mn) | 594.1 | 648.4 | 699.8 | 762.4 | 813.5 |
Net investment income (AUD Mn) | -24.8 | 138.6 | 182.2 | 207.8 | 178.9 |
Cybercrime costs (AUD Mn) | 0 | -46.4 | -39.8 | -39.7 | -34.9 |
Profit before tax (AUD Mn) | 0 | 437.9 | 711.7 | 728.8 | 927.9 |
Statutory NPAT attributable (AUD Mn) | 393.9 | 308.6 | 492.5 | 500.8 | 638.7 |
Underlying NPAT (AUD Mn) | 435.1 | 500.1 | 570.4 | 618.7 | 636.8 |
Statutory EPS (cents) | 14.3 | 11.2 | 17.9 | 18.2 | 23.2 |
Underlying EPS (cents) | 15.8 | 18.2 | 20.7 | 22.5 | 23.1 |
Ordinary DPS, fully franked (cents) | 13.4 | 14.6 | 16.6 | 18.0 | 19.2 |
Payout ratio of underlying NPAT (%) | 84.8 | 80.5 | 80.1 | 80.1 | 83.0 |
Margin
| Margin | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Group operating margin (%) | 8.3 | 8.3 | 8.6 | 8.9 | 8.9 |
Underlying net margin (%) | 6.1 | 6.4 | 7.0 | 7.2 | 7.0 |
Statutory net margin (%) | 5.5 | 4.0 | 6.0 | 5.8 | 7.0 |
Health Insurance gross margin (%) | 0 | 16.1 | 16.5 | 17.0 | 17.0 |
Dividends & Capital Returns and Margin Analysis (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total equity (AUD Mn) | 0 | 2,336.1 | 2,410.7 |
Capital employed after unpaid dividend (AUD Mn) | 0 | 2,055.2 | 2,110.5 |
Health Insurance capital employed (AUD Mn) | 0 | 1,332.2 | 1,323.8 |
Medibank Health capital employed (AUD Mn) | 0 | 412.0 | 559.8 |
Unallocated capital (AUD Mn) | 186.2 | 251.9 | 182.9 |
Health Insurance required capital (AUD Mn) | 1,161.6 | 1,195.8 | 1,197.4 |
Required capital ratio (%) | 14.1 | 14.0 | 13.3 |
PCA coverage ratio (x) | 1.8 | 1.8 | 1.9 |
Total investment portfolio, spot (AUD Mn) | 0 | 0 | 3,352.6 |
Cash and cash equivalents (AUD Mn) | 0 | 0 | 570.4 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Ordinary dividends determined (cents per share) | 16.6 | 18.0 | 19.2 |
Final dividend determined but unpaid (AUD Mn) | 0 | 280.9 | 300.2 |
M&A investment, Better Medical (AUD Mn) | 0 | 0 | 163.5 |
Myhealth step-up (AUD Mn) | 52.0 | 0 | 7.9 |
Margin Analysis (%)
| Ratio | FY2025 | FY2026 |
|---|---|---|
Underlying ROE on average equity (%) | 0 | 26.8 |
Statutory ROE on average equity (%) | 0 | 26.9 |
Effective tax rate (%) | 30.1 | 30.3 |
Underlying spread to RBA cash rate (%) | 1.66 | 1.77 |
Fund portfolio return, reported (%) | 6.38 | 5.71 |
Business Lines
| Line | FY2025 | FY2026 |
|---|---|---|
Resident PHI premium (AUD Mn) | 7,908.8 | 8,267.9 |
Non-resident PHI premium (AUD Mn) | 302.2 | 317.2 |
Medibank Health revenue (AUD Mn) | 485.2 | 634.8 |
Resident PHI growth YoY (%) | 0 | 4.5 |
Non-resident PHI growth YoY (%) | 0 | 5.0 |
Medibank Health growth YoY (%) | 0 | 30.8 |
Point Details
| Point | Price (AUD) |
|---|---|
Jun 2024 (OAIC filing day) | 3.70 |
Jan 2025 | 3.79 |
28 Aug 2025 (FY2025 result) | 5.15 |
17 Feb 2026 | 4.52 |
20 Mar 2026 | 4.21 |
5 May 2026 | 4.73 |
Post-FY2026 result (latest snapshot) | 5.28 |
Valuation Multiples
| Multiple | Medibank | Comment |
|---|---|---|
P/E on FY2026 underlying EPS 23.1c (x) | 22.9 | Computed |
P/E on statutory EPS 23.2c (x) | 22.8 | Computed |
Dividend yield, cash (%) | 3.6 | 19.2c / A$5.28; about 5.2% grossed-up for franking |
P/B on equity A$2,410.7m (x) | 6.0 | Computed |
Peer nib (NHF) | — | Not captured |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (cents) | 6.1 | 6.3 | 7.2 | 7.8 | 8.3 |
Final DPS (cents) | 7.3 | 8.3 | 9.4 | 10.2 | 10.9 |
Total DPS (cents) | 13.4 | 14.6 | 16.6 | 18.0 | 19.2 |
Analyst Conclusions
Management FY2027 guidance.
-
Disciplined resident market-share growth with improved Medibank-brand volume.
-
Resident gross margin broadly consistent with FY2026, absorbing the A$74.8m benefit unwind.
-
Solid non-resident gross profit growth.
-
Medibank Health profit growth of about 25%.
-
About A$10m of productivity savings.
-
Cyber costs below A$20m.
-
An ongoing M&A pipeline in primary care and wellbeing.
Consensus. Pre-result consensus assumed about 1.3% FY2027 policyholder growth (Ord Minnett). Detailed FY2027 EPS consensus is n.d.
Bull case
-
Earnings mix shift. Medibank Health growing about 25% in FY2027 towards more than A$200m by FY2030 would lift its share of group operating profit from about 12% to around 20%, supporting a higher multiple.
-
Capital release. Removal of the A$250m APRA overlay, plus PCA coverage of 1.9x and no debt, creates room for M&A or special returns.
-
Defensive compounding. Operating profit has grown each year since FY2022 (about 8% CAGR), with a stable 17% HI gross margin and a franked yield of about 3.6%.
Bear case
-
Competitive drift. Share fell to 26.3%, 2H26 growth was only +0.2% and lapses spiked. Price rises above the industry (5.1% vs 4.41%) risk further switching.
-
Claims normalisation. The non-recurring A$74.8m benefit plus higher hospital indexation could squeeze FY2027 resident margins if the April 2027 premium round is constrained.
-
Litigation tail. The OAIC penalty and class-action damages, now with the Deloitte reports in evidence, are unprovisioned and could be material against about A$637m of annual NPAT.
Catalysts and monitorables (next 12 months)
-
18 Nov 2026 AGM: remuneration vote; director elections.
-
APRA quarterly market-share data.
-
1H FY2027 result (Feb 2027): resident growth, Better Medical integration, claims trends.
-
April 2027 premium round approval.
-
Rulings or settlement discussions in the OAIC and class-action proceedings.
-
Any APRA decision on the A$250m overlay.
-
RBA cash-rate path.
-
Further primary-care or wellbeing acquisitions.
-
Non-resident student-visa settings.
Analyst verdict. Medibank enters its 51st year as a high-quality, defensive franchise in the middle of a long strategic transition. The insurance core is efficient and well capitalised. An 8.0% expense ratio, a 17.0% gross margin, PCA coverage of 1.9x and no debt let it pay out 83% of underlying earnings while still funding acquisitions such as the A$163.5m Better Medical deal.
FY2026 showed both the strengths and the limits of the model. Group operating profit rose 6.7% and Medibank Health grew 31%. Underlying NPAT rose only 2.9%, however, because lower cash rates cut investment income. Policyholder growth also almost stalled in the second half, when competitors and aggregators pushed hard. Medibank's market share is drifting below its own scorecard levels. Its 2030 target of more than 26.8% now looks ambitious unless the Medibank brand's improved acquisition rate holds.
The equity story increasingly rests on Medibank Health. It must almost double profit by FY2030, integrate 168 clinics, and bring the JV hospitals to break-even, while also showing that owning care lowers claims costs. The early evidence is encouraging: 27k home-hospital admissions, community care in profit and a growing Live Better membership. The segment is still only about 12% of operating profit.
The biggest swing factor is legal, not operational. The OAIC penalty and the consumer and shareholder class actions remain unprovisioned, and the Deloitte reports must now be produced. At about 23x underlying earnings and a 3.6% franked yield, the stock prices in much of the defensive quality. We see Medibank as a core holding with balanced risk and reward. The upside depends on capital release when the APRA overlay ends and on Medibank Health's delivery. The downside is limited by the franchise but exposed to litigation outcomes and share loss.
Sources consulted
-
Medibank FY2026 Results Investor Presentation (20 Aug 2026), medibank.com.au and ASX
-
Medibank FY2026 Results Media Release and Appendix 4E (20 Aug 2026)
-
Medibank Annual Report 2026 release and ASX cover letter (16 Sep 2026); newsroom release on Annual Report 2026 and brand launch
-
Medibank HY2026 results media release and Appendix 4D (19 Feb 2026); InvestSMART summaries
-
Medibank FY2025 results media release (28 Aug 2025); Livewire Markets; InvestSMART summary
-
Medibank FY2024 results media release (22 Aug 2024); HY2024 release (22 Feb 2024)
-
Medibank FY2023 Appendix 4E and media release (24 Aug 2023); FY2022 media release (18 Aug 2022); FY2021 media release (25 Aug 2021)
-
Medibank newsroom: Better Medical agreement and completion; Jay Weatherill retirement; board renewal (5 Sep 2025); FY2026 key dates; business updates (May 2025, 5 May 2026); consumer class action update (20 Mar 2026); 2021 board retirements; CEO appointment
-
Medibank board page (medibank.com.au/about/company/board)
-
Rivkin (20 Aug 2026), Ord Minnett (31 Aug 2026), Motley Fool, AAP (via Newcastle Herald and others) coverage of FY2026
-
OAIC proceedings coverage: Government News, The New Daily, Capital Brief, ACS Information Age; class-action coverage: Insurance Business, Lawyerly, Reuters/Teiss
-
APRA Quarterly Private Health Insurance Statistics, March 2026; Insurance Business on APRA 2024–25 insurer statistics; CHOICE market-share and premium analysis (2025–2026)
-
InvestSMART and Market Index price, dividend and director-trade pages; Medical Republic and AusDoc on Better Medical
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Other roles / background |
|---|---|---|---|
Mike Wilkins AO (BCom, MBA, FAICD, FCA) | Independent Chair; Chair, Nomination Committee | Director May 2017; Chair 1 Oct 2020 | Former QBE Chair (to May 2026); former IAG MD & CEO; former AMP Executive Chair; director, Scentre Group |
David Koczkar | Managing Director & CEO | CEO 17 May 2021 | Previously Medibank executive (Chief Customer Officer / Group Executive roles) |
Dr Tracey Batten | Independent NED; Chair, People & Remuneration Committee | Aug 2017 | Chair, Accident Compensation Corporation (NZ) |
Gerard Dalbosco | Independent NED; Chair, Audit Committee | May 2021 | Director, Mercy Health & Aged Care; Committee for Melbourne |
Peter Everingham | Independent NED; Chair, Investment & Capital Committee | Mar 2022 | — |
Kathryn Fagg AO | Independent NED; Chair, Risk Management Committee | Mar 2022 | Chair of Watertrust Australia, Parks Victoria, Melbourne Recital Centre, Breast Cancer Network Australia |
Jacqueline (Jacquie) Hey | Independent NED | Nov 2025 | Former Chair, Bendigo and Adelaide Bank |
Dr Lisa McIntyre | Independent NED | Nov 2025 | Chair, Women for Change Committee of the LBW Trust |
Executive Leadership Team
| Name | Role |
|---|---|
David Koczkar | Chief Executive Officer |
Mark Rogers | Group Lead – Chief Financial Officer & Group Strategy |
Robert Read | Chief Executive, Amplar Health |
Milosh Milisavljevic | Chief Customer Officer (per FY2024 coverage) |
Board & Management Changes
| Date | Director | Shares | Price (AUD) | Value (AUD) |
|---|---|---|---|---|
23 Feb 2026 | Lisa McIntyre | 22,370 | 4.48 | 100,217 |
27 Feb 2026 | Peter Everingham | 25,000 | 4.41 | 110,250 |
2 Mar 2026 | Jacqueline Hey | 11,448 | 4.42 | 50,600 |
Competitive Landscape
Market Share by Competitor
| Competitor | Market share (%) | Ownership | Positioning |
|---|---|---|---|
Medibank (incl. ahm) | 26.5 (Medibank-reported APRA figure for Mar 2026: 26.3) | Listed | Largest by share; two-brand strategy |
Bupa HI | 25.5 | UK mutual-owned group | Close #2; strong in health services (dental, optical, aged care) |
HCF | 12.8 | Not-for-profit | NSW-centric; aggressive on Gold product pricing |
nib | 9.8 | Listed (ASX: NHF) | Growth-oriented; strong in international and NZ |
HBF | 7.9 | Member-owned | WA-dominant; lowest 2026 premium rise (2.15%) |
Defence Health | ~2.0 | Not-for-profit | Niche, restricted fund |
Australian Unity, Teachers Health, GMHBA, CBHS, HIF | each ~1–3 | Various | Regional or restricted funds |
Key Competitors
| Competitor | Segment | Note |
|---|---|---|
Sonic Healthcare (IPN) | GP clinics | About 200+ centres and about 2,000 GPs, slightly larger than Medibank's ~168 clinics and ~1,750 GPs (AusDoc) |
Bupa | GP and dental clinics | Expanding into GP clinics |
Calvary, Silver Chain, others | Home and community care | Hospital-in-the-home and community nursing |
Peer Comparison FY2025
| Metric | Medibank Private (fund entity) | Bupa HI | HCF |
|---|---|---|---|
Insurance revenue FY2025 (AUD Bn) | 7.95 | 8.70 | 4.14 |
Profit after tax FY2025 (AUD Mn) | 574 | 594 | 191 |
Net margin (%) | 7.2 | 6.8 | 4.6 |
Fund-level net investment income (AUD Mn) | 194 | 171 | 0 |
Recent Developments
--



